Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×

written by

Donald Frei, MD

Dr. Donald Frei is an NeuroInterventional Surgeon based in Denver, Colorado

April 21, 2017

COMPASS Trial: A Direct Aspiration First Pass Technique

Intravenous (IV) tissue plasminogen activator (tPA) administration has been shown to be safe and effective for treatment of Acute Ischemic Stroke (AIS) within 3 hours of symptom onset, and newer evidence has shown potential benefit out to 4.5 hours.

Mechanical thrombectomy, the mechanical removal of blood clots, for AIS patients has been shown in clinical trials to be safe up to 8 hours after symptom onset. Recent trials utilizing advanced imaging to identify patients with large vessel occlusions amenable to intra-arterial thrombectomy (IAT) have shown superiority endovascular therapy over medical therapy to result in improved patient functional outcomes. Pilot data utilizing the ADAPT (A Direct Aspiration First Pass Technique) approach has shown superior technical results with similar functional outcomes while lowering procedure time and device costs versus traditional stent retriever as a first line therapy approaches.

Principal Investigator: Donald Frei, MD

For more information about this trial, please contact Alicia Drew, Director, Research and Physician Services at Radiology Imaging Associates.

If you would like to explore more clinical information about this trial, please see the trial page on ClinicalTrials.gov